Skip to content

MDMA: all studies

Page 297 of 345: studies 2,961 to 2,970 of 3,446, newest first. Back to the MDMA overview

Research

Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Ayahuasca Use in a Satanic Ritual: A Case Report

Cureus April 20, 2022 Maryam Bayat Mokhtari, Moein Bayat Mokhtari, Blanca Z Rodriguez et al. 3 citations

Ayahuasca is a psychedelic blend originating from South America that has been used for hundreds of years by local tribes in ritualistic ceremonies. For the last few decades, its usage has expanded to North America in various mindfulness retreats that can benefit from its hallucinogenic properties. In this case report, our patient had attended a satanic ritual where he had consumed copious...

Positive Affect and Letheby's Naturalization of Psychedelic Therapy

Philosophy and the Mind Sciences April 19, 2022 Sarah J. Hoffman 8 citations

Letheby’s naturalistic theory of psychedelic therapy argues that the therapeutic power of psychedelics lies in their ability to allow individuals “to discover the contingency, mutability and simulatory nature of their own sense of identity and habitual modes of attention.” The general shape of this project is persuasive; it is hard to see how the claim that successful therapy must involve...

DOI: 10.33735/phimisci.2022.9285 (opens in new tab) Affect linguistics Conceptualization Psychotherapist Naturalization +5

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

Molecules April 13, 2022 Henry Lowe, Ngeh J. Toyang, Blair Steele et al. 53 citations

The word “psychedelic” (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic drugs such as N,N-DMT/DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamide), MDMA...

Demystifying Psychedelic Treatments in Psychiatry: Is Ego Dissolution the Solution?

Psychiatric News April 1, 2022 Michael Avissar, A. J. Ambrose

A growing body of research suggests that psychedelic compounds may be useful for treating patients with certain disorders. As highlighted by several sessions at the APA Annual meeting, there’s a growing renewed interest in psychedelics, which are compounds that induce changes in thought, perception, and mood, in the clinical and research communities. Classic psychedelics refer to a subset whose...

Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019

Frontiers in Epidemiology March 23, 2022 Alan K. Davis, Brooke J. Arterberry, Yitong Xin et al. 20 citations

Background The current study is one of the first to examine race, ethnic, and sex differences in the prevalence of and trends in hallucinogen use among lifetime users in the United States. Methods Data came from the 2015–2019 National Survey on Drug Use and Health and included respondent's reporting ever-using hallucinogens ( n = 41,060; female = 40.4%). Descriptive and multinomial logistic...

DOI: 10.3389/fepid.2022.876706 (opens in new tab) Psilocybin Demography Pacific islanders Ethnic group +3

Rediscovering psychedelics

C&EN Global Enterprise March 7, 2022 Bethany Halford

Over the past decade, psychedelic compounds like psilocybin and ecstasy have emerged as potentially life-changing treatments for mental illnesses, including major depressive disorder and posttraumatic stress disorder. Read on to learn how some companies are trying to bring these once-demonized drugs to market and how others are hoping to use chemistry to eliminate their hallucinogenic effects—a...

Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy

Frontiers in Psychology March 4, 2022 Agnieszka D. Sekula, Luke A. Downey, Prashanth Puspanathan 27 citations

Psychotherapy with the use of psychedelic substances, including psilocybin, lysergic acid diethylamide (LSD), ketamine, and 3,4-methylenedioxymethamphetamine (MDMA), has demonstrated promise in treatment of post-traumatic stress disorder (PTSD), anxiety, addiction, and treatment-resistant depression. Psychedelic-assisted psychotherapy (PP) represents a unique psychopharmacological model that...

Springtime for psychopharmacology

Journal of Psychopharmacology March 1, 2022 Catherine Bird, A. H. Young

As we head into the (Northern Hemisphere) spring, the Journal publishes another set of papers which illustrate the robust health of the science of psychopharmacology. Once again, papers mostly focus on psychedelic drugs and related topics reflecting the zeitgeist (Young, 2022). de Wit et al. (2022) explore translational challenges and opportunities between clinical research and laboratory...

(2-Aminopropyl)benzo[β]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice.

Neuropsychopharmacology March 1, 2022 Deborah Rudin, John D. Mccorvy, Grant C. Glatfelter et al. 18 citations

Derivatives of (2-aminopropyl)indole (API) and (2-aminopropyl)benzofuran (APB) are new psychoactive substances which produce stimulant effects in vivo. (2-Aminopropyl)benzo[β]thiophene (APBT) is a novel sulfur-based analog of API and APB that has not been pharmacologically characterized. In the current study, we assessed the pharmacological effects of six APBT positional isomers in vitro, and...

DOI: 10.1038/s41386-021-01221-0 (opens in new tab) Full text (opens in new tab) Psychedelics Neuropharmacology Therapeutic applications Drug discovery

Micro-dosing psychedelics as a plausible adjunct to psychosexual and couple’s therapy: a qualitative insight

Sexual & Relationship Therapy February 28, 2022 Lucy Jacobs, S. Banbury, J. Lusher

Abstract Background: Research has predominated among the therapeutic application of psychedelics for varied psychopathologies and yet remains limited when supporting sexual behaviour intimacy among couples; particularly those who micro-dose. Method: Using semi-structured interviews, this qualitative study explored the micro-dosing sexual experiences of four partnered men and women aged 20–35...